AVN944 (VX-944, Vertex Pharmaceuticals, Cambridge, MA, USA) is an IMPDH2 inhibitor designed to disrupt the metabolic pathways crucial for tumor cell proliferation and survival. This evidence concerns the gene IMPDH2 and neoplasm.